Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alliancaude e Participacoes's revenue for the
three
months ended in Sep. 2025 was R$328 Mil.
Its revenue for the trailing twelve months (TTM) ended in Sep. 2025 was R$1,240 Mil.
Alliancaude e Participacoes's Revenue per Share for the
three
months ended in Sep. 2025 was R$2.16.
Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2025 was R$8.70.
Warning Sign:
Allianca Saude e Participacoes SA revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Alliancaude e Participacoes was -14.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 2.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 3.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 2.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 11 years, Alliancaude e Participacoes's highest 3-Year average Revenue per Share Growth Rate was 9.80% per year. The lowest was -5.10% per year. And the median was 2.10% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Alliancaude e Participacoes Revenue Related Terms
Alliancaude e Participacoes Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Alliancaude e Participacoes's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alliancaude e Participacoes Revenue vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Alliancaude e Participacoes's Revenue distribution charts can be found below:
* The bar in red indicates where Alliancaude e Participacoes's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1,240 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alliancaude e Participacoes (BSP:AALR3) has a Revenue of R$1,240 Mil as of Sep. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Alliancaude e Participacoes and its competitors.
Is Alliancaude e Participacoes' Revenue too high?
Alliancaude e Participacoes' current Revenue is R$1,240 Mil. Overall, Alliancaude e Participacoes has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alliancaude e Participacoes' Revenue compare to TMO and DHR?
Alliancaude e Participacoes' Revenue of R$1,240 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Diagnostics & Research company?
A good Revenue depends on the Medical Diagnostics & Research industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Alliancaude e Participacoes and its competitors. Alliancaude e Participacoes's current Revenue is R$1,240 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alliancaude e Participacoes stock overvalued right now?
Based on GuruFocus' analysis, Alliancaude e Participacoes (BSP:AALR3) is currently considered Possible Value Trap. The stock's GF Value™ is R$9.41, compared to a current price of R$3.25 — trading 65.5% below its estimated fair value. The current Revenue is R$1,240 Mil. Alliancaude e Participacoes' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Alliancaude e Participacoes (BSP:AALR3), the current Revenue is R$1,240 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alliancaude e Participacoes (BSP:AALR3) Overvalued in 2026?
Based on GuruFocus' analysis, Alliancaude e Participacoes stock appears to be undervalued.
The current stock price of R$3.25 is trading 65.5% below its estimated GF Value™ of R$9.41.
GuruFocus considers Alliancaude e Participacoes to be Possible Value Trap.
Key valuation signals for BSP:AALR3:
Revenue: R$1,240 Mil
GF Value™: R$9.41 vs. price of R$3.25 (65.5% below fair value)
No single metric tells the full story. See the BSP:AALR3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allianca Saude e Participacoes SA formerly Centro de Imagem Diagnosticos SA - Alliar is a diagnostic imaging company consisting of MRI machines, CT scanners and ultrasound machines. Its products include diagnostic medicine, diagnostic imaging and clinical analysis. The company is also engaged in the import of medical and hospital equipment, diagnosis kits, and related goods; Providing health consulting, advisory, courses and lectures.
48GF Score
Get the complete analysis for BSP:AALR3
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:AALR3 has been successfully added to your 
